VRDNViridian Therapeutics, Inc.\DE
Pharmaceutical Preparations
- Revenue
- $71M
- 23360% YoY
- Operating margin
- -512.9%
- 99% YoY
- EBITDA
- −$363M
- 22% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$5M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired63% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $3M | $2M | $314K | $302K | $71M | 23360% |
| Operating income | −$80M | −$134M | −$254M | −$299M | −$363M | 22% |
| Net income | −$79M | −$130M | −$238M | −$270M | −$343M | 27% |
| Operating cash flow | −$55M | −$94M | −$184M | −$232M | −$276M | 19% |
| Capex | $338K | $797K | $898K | $511K | $495K | 3.1% |
| Stock-based comp | $14M | $20M | $67M | $42M | $44M | 5.1% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 189 | 125 |
| FY2024 | — | — | 117 | 93 |
| FY2023 | — | — | 132 | 94 |
| FY2022 | — | — | 178 | 90 |
| FY2021 | — | — | 120 | 100 |